Cargando…

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans

BACKGROUND: Injectable opioid agonist treatment (iOAT) is an emerging evidence-based option in the continuum of care for opioid use disorder in parts of Canada. Our study objective was to identify and describe iOAT programs operating during the ongoing opioid overdose crisis. METHODS: We conducted 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eydt, Erin, Glegg, Stephanie, Sutherland, Christy, Meador, Karine, Trew, Michael, Perreault, Michel, Goyer, Marie-Ève, Le Foll, Bernard, Turnbull, Jeffrey, Fairbairn, Nadia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Joule Inc. or its licensors 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034381/ https://www.ncbi.nlm.nih.gov/pubmed/33622764 http://dx.doi.org/10.9778/cmajo.20200021

Ejemplares similares

“COVID just kind of opened a can of whoop-ass”: The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada
por: Glegg, Stephanie, et al.
Publicado: (2022)

The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19
por: McCrae, Karen, et al.
Publicado: (2022)

Implementation of Interventions and Policies on Opioids and Awareness of Opioid-Related Harms in Canada: A Multistage Mixed Methods Descriptive Study
por: Goyer, Camille, et al.
Publicado: (2022)

The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting
por: Mackay, Lindsay, et al.
Publicado: (2021)

Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy
por: Moallef, Soroush, et al.
Publicado: (2022)

Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review
por: Pijl, Em M., et al.
Publicado: (2022)

Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021
por: Rosic, Tea, et al.
Publicado: (2023)

The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada
por: Franklyn, Alexandra M., et al.
Publicado: (2017)

Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis
por: Eugenia Socias, M., et al.
Publicado: (2023)

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance
por: Meyers-Pantele, Stephanie A., et al.
Publicado: (2022)

Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey
por: Kouyoumdjian, Fiona G., et al.
Publicado: (2018)

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Problematic Opioid Use: A Scoping Literature Review of Profiles
por: Archambault, Léonie, et al.
Publicado: (2022)

Trends in smoking during pregnancy stratified by the use of opioid agonist therapy and the contribution of smoking to poor outcome in neonates prenatally exposed to opioid agonist treatment
por: Kelty, Erin, et al.
Publicado: (2023)

Better agonist for the opioid receptors
por: Badshah, Syed Lal, et al.
Publicado: (2018)

Evidence of Increased Age and Sex Standardized Death Rates Among Individuals Who Accessed Opioid Agonist Treatment Before the Era of Synthetic Opioids in Ontario, Canada
por: Morin, Kristen A, et al.
Publicado: (2021)

Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Characterizing opioid agonist therapy uptake and factors associated with treatment retention among people with HIV in British Columbia, Canada
por: Yazdani, Kiana, et al.
Publicado: (2023)

Strategies to Identify Patient Risks of Prescription Opioid Addiction When Initiating Opioids for Pain: A Systematic Review
por: Klimas, Jan, et al.
Publicado: (2019)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Therapeutic Potential of Kappa Opioid Agonists
por: Beck, Tyler C., et al.
Publicado: (2019)

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
por: Russell, Cayley, et al.
Publicado: (2022)

Correction to: Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada
por: Morin, Kristen A., et al.
Publicado: (2019)

Evaluating the effectiveness of concurrent opioid agonist treatment and physician-based mental health services for patients with mental disorders in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2020)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
por: Tahsin, Farah, et al.
Publicado: (2022)

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis
por: Bodkin, Claire, et al.
Publicado: (2021)

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2022)

Access to tablet injectable opioid agonist therapy in rural and smaller urban settings in British Columbia, Canada: a qualitative study
por: Bardwell, Geoff, et al.
Publicado: (2023)

Interim opioid agonist treatment for opioid addiction: a systematic review
por: Samsó Jofra, Laura, et al.
Publicado: (2022)

“We’re Home Now”: How a Rehousing Intervention Shapes the Mental Well-Being of Inuit Adults in Nunavut, Canada
por: Perreault, Karine, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis
por: Garg, Ria, et al.
Publicado: (2022)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
por: Palis, Heather, et al.
Publicado: (2021)

Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study
por: Morin, Kristen A, et al.
Publicado: (2022)

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
por: Day, Nathaniel, et al.
Publicado: (2022)

Virtual Overdose Response for People Who Use Opioids Alone: Protocol for a Feasibility and Clinical Trial Study
por: Bristowe, Sean Kristina, et al.
Publicado: (2021)

Collembola of Canada
por: Turnbull, Matthew S., et al.
Publicado: (2019)

Social structural factors that shape assisted injecting practices among injection drug users in Vancouver, Canada: a qualitative study
por: Fairbairn, Nadia, et al.
Publicado: (2010)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
por: Bharat, Chrianna, et al.
Publicado: (2022)

Slow release oral morphine versus methadone for the treatment of opioid use disorder
por: Klimas, Jan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0rtl0i1sa6t3s352vq12v0l0c1